Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer's Disease: A UK Evaluation Using Discrete-Event Simulation

Author： Getsios Denis

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.28, Iss.5, 2010-05, pp. : 411-427

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Donepezil is better tolerated than rivastigmine in mild-to-moderate Alzheimer's disease

Inpharma, Vol. 1, Iss. 1258, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Donepezil a smart choice for mild-to-moderate AD in the UK

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 603, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Nicergoline in the Treatment of Mild-to-Moderate Alzheimer's Disease: A European Multicentre Trial

By Winblad B.

Clinical Drug Investigation, Vol. 21, Iss. 9, 2001-09 ,pp. : 621-632

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Treatment Options in Patients with Alzheimer's Disease: A Systematic Review of Cost-Effectiveness Analyses

By Pouryamout Laura

Drugs, Vol. 72, Iss. 6, 2012-04 ,pp. : 789-802

Adis International

Access to resources Recommend Favorite

Apolipoprotein E4 (ApoE4) genotype and/or gender do not appear to predict a response to donepezil in patients with mild-to-moderate Alzheimer's disease

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite